According to a new meta-analysis in the Journal of Clinical Endocrinology & Metabolism, everyday over-the-counter antacids—specifically Proton Pump Inhibitors (PPIs)—may provide an unexpected clinical advantage for diabetic patients by enhancing blood sugar regulation.
While these medications helped manage existing cases, researchers emphasized they do not prevent the onset of the disease in the general population.
Key Findings: A Boost for Diabetes Management
The study analyzed data from thousands of participants to determine how PPIs (such as Prilosec, Nexium, and Prevacid) affect glucose levels.
- HbA1c Reduction: For individuals with diabetes, adding an antacid to standard care reduced HbA1c levels by an average of 0.36%.
- Fasting Glucose: The treatment lowered fasting blood sugar by 10 mg/dl.
- No Preventive Power: For those without diabetes, taking antacids did not significantly lower the risk of developing the condition.
Clinical Implications
Researchers suggest that doctors should account for this "glucose-lowering effect" when prescribing antacids to diabetic patients for acid reflux or ulcers.
"Prescribing antacids as an add-on to standard care was superior to standard therapy in decreasing HbA1c levels," says study author Dr. Carol Chiung-Hui Peng.
Common PPIs Mentioned in the Study
If you are managing diabetes, you may already be familiar with these common brands:
- Omeprazole (Prilosec)
- Esomeprazole (Nexium)
- Lansoprazole (Prevacid)
- Pantoprazole (Protonix)
Summary Comparison
| Goal | Impact of Antacids (PPIs) |
| Blood Sugar Control | Improved (HbA1c down 0.36%, Fasting Glucose down 10 mg/dl) |
| Diabetes Prevention | No Effect (Risk remains the same for the general public) |
0 Comments